IWP-2 (GMP)

[1]Guan J et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022;605 (7909) :325-331. |[2]Hamad S, et al. Generation of human induced pluripotent stem cell-derived cardiomyocytes in 2D monolayer and scalable 3D suspension bioreactor cultures with reduced batch-to-batch variations. Theranostics. 2019 Sep 25;9 (24) :7222-7238. |[3]Le MNT, et al. Auto/paracrine factors and early Wnt inhibition promote cardiomyocyte differentiation from human induced pluripotent stem cells at initial low cell density. Sci Rep. 2021 Nov 2;11 (1) :21426. |[4]Taniguchi J, et al. A synthetic DNA-binding inhibitor of SOX2 guides human induced pluripotent stem cells to differentiate into mesoderm. Nucleic Acids Res. 2017 Sep 19;45 (16) :9219-9228. |[5]Lian X, Zhang J, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/β-catenin signaling under fully defined conditions. Nat Protoc. 2013 Jan;8 (1) :162-75.

Nat Protoc. 2024 Jul;19 (7) :1911-1939.|ACS Comb Sci. 2019 Dec 9;21 (12) :805-816.|Adv Mater. 2021 Dec;33 (49) :e2104829.|Autoimmunity. 2023 Dec;56 (1) :2182741.|Biocell. 2025 Feb 28.|Biochem Pharmacol. 2019 Nov;169:113608.|Bioengineering (Basel) . 2023 Jun 9;10 (6) :702.|bioRxiv. 2024 Mar 13.|Cell Rep Methods. 2024 May 8:100777.|Clin Sci. 2023 Jan 13;137 (1) :109-127.|Dev Cell. 2020 Dec 21;55 (6) :679-694.e11.|eNeuro. 2025 Jan 9:ENEURO.0347-24.2024.|Exp Cell Res. 2022 Nov 11;422 (1) :113416.|Exp Ther Med. 2020 Mar;19 (3) :1701-1710.|J Appl Polym Sci. 2024 Sep 25.|J Cell Physiol. 2020 Jul;235 (7-8) :5811-5822.|J Inflamm Res. 2024 Nov 19:17:8945-8964.|Microb Pathog. 2024 Sep 21:106960.|Neoplasia. 2024 Dec 30:60:101096.|Patent. US20180263995A1.|PLoS One. 2024 Jan 5;19 (1) :e0287206.|SSRN. 2024 Mar 26.|Stem Cell Res Ther. 2024 Oct 8;15 (1) :350.|Stem Cells Transl Med. 2021 May;10 (5) :743-755.|Toxicon. 2026 Jan:269:108660.